Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5883046 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 9 Pages |
Abstract
BackgroundThe prognosis of myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) is very heterogeneous.Patients and MethodsWe analyzed the prognostic value of several genes in a cohort of 85 MDS and AML patients.ResultsOverexpression of glycogen synthase 1 and macrophage migration inhibitory factor genes had an adverse outcome in multivariate analysis (PÂ = .003 and PÂ < .001, respectively). Furthermore, the higher expression of myelocytomatosis oncogene was associated with a lower response to azacitidine (PÂ = .03).ConclusionIn the current study we identified a specific gene expression profile as prognostic factors for response to azacitidine and survival in MDS and AML.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Jose F. Falantes, Pablo Trujillo, Jose I. Piruat, Cristina Calderón, Francisco J. Márquez-Malaver, Beatriz MartÃn-Antonio, Africa Millán, Marina Gómez, Jose González, Maria L. Martino, Isabel Montero, RocÃo Parody, Ildefonso Espigado,